Lipid nanoparticles as a potential treatment for beta-thalassemia

Lipid nanoparticles as a potential treatment for beta-thalassemia represent an emerging and promising approach in the field of advanced therapies. In this HELIOS and HemaFAIR webinar, Dr. Ana Belén Pérez Oliva will present current research on the use of lipid nanoparticles for targeted gene and cell therapy applications in beta-thalassemia.

Connection Link: https://teams.microsoft.com/meet/374577558482201?p=Kcvp6o4Khk3PFsbj8s

Lipid nanoparticles are gaining increasing attention as efficient delivery systems for nucleic acids and therapeutic molecules. Their ability to transport genetic material into cells opens new possibilities for treating inherited blood disorders such as beta-thalassemia, addressing underlying molecular defects and improving patient outcomes.

This webinar will explore:

• The fundamentals of lipid nanoparticles and their role in gene and cell therapy
• How these systems can be applied to beta-thalassemia treatment
• Current challenges and limitations in delivery efficiency and safety
• Recent advances and research developments in the field

This session aims to provide participants with a clear understanding of how innovative delivery technologies can contribute to next-generation therapies for hemoglobinopathies.

Target audience: researchers, clinicians, and healthcare professionals interested in gene therapy, nanomedicine, hematology, and emerging treatments for rare blood disorders.